1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
FEATURED COMPANIES
- Amgen Inc.
- CSL Ltd.
- Horizon Therapeutics Plc
- Merck & Co., Inc.
- Novartis AG
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Immune thrombocytopenia is common among young women, and its risk is higher in people with diseases such as rheumatoid arthritis, HIV, hepatitis, lupus, and antiphospholipid syndrome. The prevalence of these diseases is high across the world. For instance, in 2016, over a million people in the US were diagnosed with HIV infection, and nearly 1% of the adults in the US had Hepatitis C. The growing incidences of such risk factors will increase the prevalence of immune thrombocytopenia. This will increase the demand for treatment options, thereby driving the growth of the global immune thrombocytopenia market size at a CAGR of nearly 5% during the forecast period.
Market Overview
Expected approvals for late-stage pipeline molecules
The market is witnessing accelerated growth in the number of molecules in the pipeline for the treatment of immune thrombocytopenia. At present, there are over 5 therapeutics to treat immune thrombocytopenia. These drugs are in the late stages of development and are slated to receive marketing approvals during the forecast period.
Availability of substitutes
The side effects associated with the available drugs for the treatment of immune thrombocytopenia are forcing healthcare practitioners to adopt alternative treatment options such as platelet transfusion and surgery. These treatment options have higher efficacies when compared to the available drugs. This is expected to pose a challenge to the growth of the global immune thrombocytopenia market size.
Competitive Landscape
The market appears to be fragmented with several players occupying the market share. Companies such as Amgen Inc. and CSL Ltd. Have intensified the competition. Factors such as the high prevalence of associated risk factors for immune thrombocytopenia and the expected approvals of late-stage pipeline molecules will provide significant growth opportunities for immune thrombocytopenia drug manufacturers. Amgen Inc., CSL Ltd., Horizon Therapeutics Plc, Merck & Co. Inc., Novartis AG, and Rigel Pharmaceuticals Inc. are some of the major companies covered in this report.
Market Overview
Expected approvals for late-stage pipeline molecules
The market is witnessing accelerated growth in the number of molecules in the pipeline for the treatment of immune thrombocytopenia. At present, there are over 5 therapeutics to treat immune thrombocytopenia. These drugs are in the late stages of development and are slated to receive marketing approvals during the forecast period.
Availability of substitutes
The side effects associated with the available drugs for the treatment of immune thrombocytopenia are forcing healthcare practitioners to adopt alternative treatment options such as platelet transfusion and surgery. These treatment options have higher efficacies when compared to the available drugs. This is expected to pose a challenge to the growth of the global immune thrombocytopenia market size.
Competitive Landscape
The market appears to be fragmented with several players occupying the market share. Companies such as Amgen Inc. and CSL Ltd. Have intensified the competition. Factors such as the high prevalence of associated risk factors for immune thrombocytopenia and the expected approvals of late-stage pipeline molecules will provide significant growth opportunities for immune thrombocytopenia drug manufacturers. Amgen Inc., CSL Ltd., Horizon Therapeutics Plc, Merck & Co. Inc., Novartis AG, and Rigel Pharmaceuticals Inc. are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen Inc.
- CSL Ltd.
- Horizon Therapeutics Plc
- Merck & Co., Inc.
- Novartis AG
PART 01: EXECUTIVE SUMMARYPART 07: CUSTOMER LANDSCAPEPART 09: DECISION FRAMEWORK
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
List of Exhibits:
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen Inc.
- CSL Ltd.
- Horizon Therapeutics Plc
- Merck & Co., Inc.
- Novartis AG
The following companies are recognised as the key players in the global immune thrombocytopenia market: Amgen Inc., CSL Ltd., Horizon Therapeutics Plc, Merck & Co. Inc., Novartis AG, and Rigel Pharmaceuticals Inc.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing number of awareness programs.”
According to the report, one of the major drivers for this market is the high prevalence associated risk factors for immune thrombocytopenia.
Further, the report states that one of the major factors hindering the growth of this market is the availability of substitutes.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing number of awareness programs.”
According to the report, one of the major drivers for this market is the high prevalence associated risk factors for immune thrombocytopenia.
Further, the report states that one of the major factors hindering the growth of this market is the availability of substitutes.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Amgen Inc.
- CSL Ltd.
- Horizon Therapeutics Plc
- Merck & Co., Inc.
- Novartis AG
- Rigel Pharmaceuticals Inc.
Note: Product cover images may vary from those shown